loading

Mineralys Therapeutics Inc (MLYS) 最新ニュース

pulisher
Mar 27, 2025

Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.

Mar 26, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - StockTitan

Mar 25, 2025
pulisher
Mar 23, 2025

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Mar 23, 2025
pulisher
Mar 21, 2025

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus.com

Mar 21, 2025
pulisher
Mar 20, 2025

Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues

Mar 20, 2025
pulisher
Mar 20, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks

Mar 20, 2025
pulisher
Mar 19, 2025

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Major Investment Alert: Ra Capital Management Bets Big on Mineralys Therapeutics! - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Largest borrow rate increases among liquid names - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys to present hypertension drug trial results at ACC.25 - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Ex - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25 - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics Announces Data from the Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Mineralys Therapeutics : Corporate Overview March 2025 -March 17, 2025 at 08:06 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Major Breakthrough: New Hypertension Drug Data Earns Coveted ACC Late-Breaking Slot - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth - Value the Markets

Mar 14, 2025
pulisher
Mar 14, 2025

A&O Shearman advises on the USD175 million follow-on equity offering by Mineralys Therapeutics Inc. - A&O Shearman

Mar 14, 2025
pulisher
Mar 13, 2025

Mineralys Therapeutics prices $175M stock offering - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Mineralys Reports Positive Results for Hypertension Drug Lorundrostat - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Latham & Watkins Advises Mineralys Therapeutics on US$175 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP

Mar 12, 2025
pulisher
Mar 12, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga India

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Purchases New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Mineralys Therapeutics Prices $175 Million Share Offering -March 12, 2025 at 03:58 am EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Mineralys Therapeutics sets $13.50 share price for public offering By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 11, 2025

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys Therapeutics sets $13.50 share price for public offering - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test - DELCO.Today

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys Therapeutics Announces Pricing Of $175.0 Million Underwritten Public Offering Of Common Stock - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Stifel maintains Buy on Mineralys Therapeutics, $45 target By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

(MLYS) Trading Advice - Stock Traders Daily

Mar 11, 2025
pulisher
Mar 11, 2025

Mineralys launches $250 mln equity offering to fund blood pressure drug; shares dip - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Pa.-based biopharma company successfully completes two trials for hypertension drug - Pennsylvania Business Report

Mar 11, 2025
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):